Sputum colour: a useful clinical tool in non-cystic fibrosis bronchiectasis. Murray et al, Eur Respir J 2009, DOI: 10.1183/09031936.00163208 Colour of phlegm can predict outcomes for patients with ...

33.9%). On the same note, 35.4% of patients with bronchiectasis had difficulties getting a sputum culture at the beginning of an infection. Result delays were also noted by 29.6% of patients ...

The Lancet Respiratory Medicine published a phase 2 clinical study article on China's first DPP-1 inhibitor, HSK31858, led by Academician Nan-shan Zhong and Professor Wei-jie Guan from the First ...

Allergic bronchopulmonary aspergillosis is a pulmonary disease occurring in patients with asthma or cystic fibrosis, consequent to a dysregulated immune response to inhaled Aspergillus conidia.

The FDA has started a priority review of Insmed's brensocatib, which is pitching to become the first approved therapy for chronic lung disease bronchiectasis in the US. The regulator has set a ...

Find effective medications for 'Bronchiectasis treatment right here!' This page is a trusted source for both professionals and patients, detailing brand-name and generic options designed to manage ...

Surgery is essential for the effective management of bronchiectasis. Segmentectomy, while a challenging procedure, has become ...

Bronchiectasis is a chronic lung disease characterized by enlarged airways that are thickened or scarred. These permanently widened airways lead to a buildup of mucus and impaired clearance of ...

"With no treatments specifically approved for bronchiectasis, we are especially eager to present several new subgroup analyses from ASPEN, the largest Phase 3 clinical trial in bronchiectasis to ...

0 Asymptomatic Never diagnosed to have ABPA in the past, presentation with controlled asthma (according to GINA guidelines) and meeting the diagnostic criteria of ABPA (Box 6) 1 Acute Never ...